Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009
Date:7/14/2009

(247,360,000) (230,836,000) ------------ ------------ Total stockholders' equity 901,000 15,595,000 ------- ---------- TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $23,127,000 $23,057,000 =========== =========== 

    PEREGRINE PHARMACEUTICALS, INC.

    CONSOLIDATED STATEMENTS OF OPERATIONS
    FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2009


                                         2009           2008           2007
                                         ----           ----           ----

    REVENUES:
    Contract manufacturing revenue   $12,963,000     $5,897,000     $3,492,000
    Government contract revenue        5,013,000              -              -
    License revenue                      175,000        196,000        216,000
                                         -------        -------        -------

      Total revenues                  18,151,000      6,093,000      3,708,000

    COSTS AND EXPENSES:
    Cost of contract manufacturing     9,064,000      4,804,000      3,296,000
    Research and development          18,424,000     18,279,000     15,876,000
    Selling, general and
     administrative                    6,979,000      7,150,000      6,446,000
                                       ---------      ---------      ---------

      Total costs and expenses        34,467,000     30,233,000     25,618,000
                                      ----------     ----------     ----------

    LOSS FROM OPERATIONS             (16,316,000)   (24,140,000)  (21,910,000)

    OTHER INCOME (EXPENSE):
    Interest and other income            200,000        989,000      1,160,000
    Interest and other expense          (408,000)       (25,000) 
'/>"/>
SOURCE  Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
9. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
10. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
11. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... The omega-3 essential fatty acids commonly found ... sensory overload, according to research published by the ... to the information-processing problems found in people with ... disease; and other afflictions of the nervous system. ... Behavioral Neuroscience , provides more evidence that ...
(Date:12/16/2009)... Digital Pen and Paper technology and the provider of the ... that it is ranked among the Fastest Growing Technology Companies ... , ... (PRWEB) December 16, 2009 -- ... capture, digitalization and management of handwritten data. Kayentis targets the ...
(Date:12/16/2009)... low, government report shows, , , WEDNESDAY, Dec. 16 (HealthDay ... has reached almost 78 years, a record high, federal ... women can expect to live to 80.4 years on ... report from the U.S. Centers for Disease Control and ... to live longer than their parents, life expectancy in ...
(Date:12/16/2009)... Calif., Dec. 16 New research ... bioactive compounds in pistachios, and molecules present ... Pistachio oil decreases levels of an inflammatory ... tetratricopeptide repeats 2). Inflammation is a complex ... cells or irritants, and it underlies functional ...
(Date:12/16/2009)... the heart of diagnostic procedures in cardiology. The idea ... accumulates the expertise of European cardiovascular imagers, is therefore ... it is written with a patient rather than technology-based ... patient, with the aid of imaging. , The ... involving theory and practice of cardiac imaging and its ...
Breaking Medicine News(10 mins):Health News:New study links DHA type of omega-3 to better nervous-system function 2Health News:With a Revenue Growth of Over 500% During the Last 5 Years, Kayentis is Ranked on the Deloitte Technology Fast 500 -- EMEA 2009 2Health News: Life Expectancy in U.S. Hits New High 2Health News: Life Expectancy in U.S. Hits New High 3Health News:New Study Reveals Pistachios Have Anti-Inflammatory Properties 2Health News:New Study Reveals Pistachios Have Anti-Inflammatory Properties 3Health News:The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center 2Health News:The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center 3
... NHS services’, UK ‘s Health Minister Patricia Hewitt launched ... select their hospital and doctor, as well as access information on ... to put patients at the heart of the NHS and making ... a crucial part of that. “Patients will soon be able to ...
... Prevention say there has been a sudden increase in the count ... or more. ,Accordingly, not only has the proportion of ... as fast as the increase in moderate obesity), there has also ... people (BMI of 30 or more), and a 75 percent increase ...
... a view to increasing the number of organ donors, Ontario’s ... expenses and loss of pay to living donors. The ... during spring. ,British Columbia coughs up nearly ... to donate their organs. With this scheme, nearly 43 living ...
... Punjab government and its pharmacy council will frame stricter ... especially among the youth. ,Medical Education ... that the department and the pharmacy council would ensure ... qualified pharmacists to dispense medicines to consumers. ...
... could make the aggrieved die from a broken heart, scientists// said. ... in the brain in charge of memory, learning and emotion can ... that important regions in the brain get caught up in a ... ,This study is perhaps the first insightful study ...
... doctors led by Mona Raghothaman of the National Institute of ... made a strong plea for all out nationwide efforts to ... have suggested that doctors working at primary health care centers ... the patients to specialty centers. ,In a ...
Other Medicine News:Health News:NHS Online- Promise Of ‘Choices’ To Patien 2Health News:Make Treatment of Parkinsons More Affordable, Doctors Plead 2Health News:Make Treatment of Parkinsons More Affordable, Doctors Plead 3
(Date:12/16/2009)... Cohera Medical Inc. today announced the treatment of ... lead surgical adhesive product, TissuGlu®. Initiation of the ... progression of the lead product toward clinical practice. ... open-label, randomized study to investigate the safety of ... associated complications in abdominoplasty, or "tummy tuck," surgeries. ...
(Date:12/16/2009)... Dec. 16 RealMed has been ... in the 2009 Top 20 Best ... report. RealMed is a dynamic revenue ... transactions processing between healthcare providers and ... research firm specializing in vendor performance measurement ...
(Date:12/16/2009)... CareCentrix, Inc ., the nation,s leading provider ... that it has been awarded Health Utilization Accreditation ... organization that establishes quality standards for the health ... trained, qualified clinical personnel conduct and oversee the ... appeals process is in place, and that medical ...
Breaking Medicine Technology:First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 2First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 3RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 2RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 3CareCentrix Receives URAC Health Utilization Management Accreditation 2High Impact Activity May Be Good for Old Bones 61359 1High Impact Activity May Be Good for Old Bones 61359 2blue sky scrubs adds Caribbean Blue Scrubs 61357 1blue sky scrubs adds Caribbean Blue Scrubs 61357 2U S Census Bureau Daily Feature for Nov 14 61355 1
... Improved Efficacy with Higher Doses ... - ... - Dose Escalation Ongoing -, SAN FRANCISCO and ... an ongoing Phase 1-2,clinical trial of the Company,s novel androgen receptor antagonist,MDV3100, showed encouraging ...
... "A two-year,survival rate of more than ... suggests a breakthrough in this devastating disease ... and Coordinating,Investigator of the Phase IIb active-controlled ... refractory high-grade glioma, while presenting the,data at ...
Other Medicine Technology:Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting 2Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting 3Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting 4Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements 2Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements 3Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements 4
... provides fast, accurate, and reliable tests of a ... duplicates conditions for viewing far point test charts ... near point test charts at 30cm (12"). The ... test charts that can be interchanged as required. ...
A professionally designed instrument for obtaining accurate measurements of the corneal curvature. The convenient configuration also facilitates measuring contact lens curvatures....
... the benefits of IMAGEnet Lite, a standard ... PC with the Topcon TRC-NW6 or TRC-NW6S ... fundus screening package. The system incorporates the ... Topcons Non-Mydriatic retinal camera allowing a technician ...
... combines the best 32-bit software package (IMAGEnet ... offerings to bring you a fast reliable ... efficient "mid-resolution" package takes advantage of the ... the latest graphics capture technology and a ...
Medicine Products: